Join our daily newsletter At The Bell to receive exclusive market insights
- Shares in healthcare technology company Emyria (EMD) have been placed in a trading halt with a capital raise announcement anticipated later this week
- EMD has not made an indication regarding what the funds will be used for at this stage or how much will be raised
- The trading halt will continue until December 16, 2020, or when the capital raise is disclosed to the market
- In recent news, Emyria was appointed by Zelira Therapeutics (ZLD) to oversee the data collection for an observational medicinal cannabis trial
- Shares last traded at 8.5 cents apiece prior to entering a trading halt
Shares in healthcare technology company Emyria (EMD) have been placed in a trading halt with a capital raise announcement anticipated later this week.
EMD has not made an indication regarding what the funds will be used for at this stage or how much will be raised.
The trading halt will continue until December 16, 2020, or when the capital raise is disclosed to the market.
In recent news, Emyria was appointed by Zelira Therapeutics (ZLD) to oversee the data collection for an observational medicinal cannabis trial.
The trial was one of the largest observational medicinal cannabis studies ever undertaken in patients with Autism Spectrum Disorder involving a specific product range.
In August, Emyria signed a data deal with Spectrum Therapeutics U.K., the U.K. subsidiary of Canopy Growth, to design and deliver a real-world evidence platform in the U.K. to generate insights on safety and effectiveness for cannabis-based medicines.
EMD posted quarterly revenue growth of approximately 125 per cent to $647, 000 in its October quarterly report.
Shares last traded at 8.5 cents apiece prior to entering a trading halt.
